Thrombotic thrombocytopenic purpura during interferon alpha treatment for chronic myelogenous leukemia

Acta Haematol. 2000;102(3):160-2. doi: 10.1159/000040993.

Abstract

Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-alpha) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-alpha therapy for chronic myelogenous leukemia. In this case, IFN-alpha seems to be the only etiological agent.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Leukemia, Myeloid / complications
  • Leukemia, Myeloid / drug therapy*
  • Male
  • Purpura, Thrombotic Thrombocytopenic / chemically induced*
  • Purpura, Thrombotic Thrombocytopenic / complications

Substances

  • Antineoplastic Agents
  • Interferon-alpha